Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP719030.RAWQtlj8wjf5VRxCHO2Wai46to-2ISVoza7vV3GBShAz0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP719030.RAWQtlj8wjf5VRxCHO2Wai46to-2ISVoza7vV3GBShAz0130_assertion type Assertion NP719030.RAWQtlj8wjf5VRxCHO2Wai46to-2ISVoza7vV3GBShAz0130_head.
- NP719030.RAWQtlj8wjf5VRxCHO2Wai46to-2ISVoza7vV3GBShAz0130_assertion description "[Furthermore, patients affected by essential thrombocythemia who are carriers of the Janus kinase 2 Val617Phe mutation show a higher incidence of venous thromboembolism both before, and at the time of diagnosis, compared with noncarriers, and recent evidence of splanchnic and cerebral vein thrombosis in carriers of the Janus kinase 2 Val617Phe mutation has been reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP719030.RAWQtlj8wjf5VRxCHO2Wai46to-2ISVoza7vV3GBShAz0130_provenance.
- NP719030.RAWQtlj8wjf5VRxCHO2Wai46to-2ISVoza7vV3GBShAz0130_assertion evidence source_evidence_literature NP719030.RAWQtlj8wjf5VRxCHO2Wai46to-2ISVoza7vV3GBShAz0130_provenance.
- NP719030.RAWQtlj8wjf5VRxCHO2Wai46to-2ISVoza7vV3GBShAz0130_assertion SIO_000772 18600099 NP719030.RAWQtlj8wjf5VRxCHO2Wai46to-2ISVoza7vV3GBShAz0130_provenance.
- NP719030.RAWQtlj8wjf5VRxCHO2Wai46to-2ISVoza7vV3GBShAz0130_assertion wasDerivedFrom befree-20140225 NP719030.RAWQtlj8wjf5VRxCHO2Wai46to-2ISVoza7vV3GBShAz0130_provenance.
- NP719030.RAWQtlj8wjf5VRxCHO2Wai46to-2ISVoza7vV3GBShAz0130_assertion wasGeneratedBy ECO_0000203 NP719030.RAWQtlj8wjf5VRxCHO2Wai46to-2ISVoza7vV3GBShAz0130_provenance.